Aurinia Pharmaceuticals Inc. (AUPH)

Every figure this model derived for AUPH, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 176,000 PaymentsToAcquireOtherProductiveAssets 2026-06-30
cash 179,732,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 541,324,000 AssetsCurrent 2026-06-30
current liabilities 99,893,000 LiabilitiesCurrent 2026-06-30
equity 614,864,000 StockholdersEquity 2026-06-30
interest expense 4,106,000 InterestExpenseNonoperating 2026-06-30
ocf 175,243,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 311,507,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 14,620,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up AUPH on one particular measure came for.

RatioValue
cash operating margin59.31
current ratio6.06
current ratio reported5.42
deferred revenue growth92.64
dilution pct-5.13
ebit yoy189.85
fcf margin56.2
growth cv1.32
interest cover36.71
operating margin48.39
owner earnings margin51.51
revenue growth19.76
revenue growth per share26.23
roic24.03
rule of 4068.15
sbc pct revenue4.69

What to be careful about

What this model itself distrusts about AUPH's figures. Written by the derivation as it ran, not added afterwards.